AJ8 Stock Overview
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Agenus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.80 |
| 52 Week High | US$37.22 |
| 52 Week Low | US$7.80 |
| Beta | 1.28 |
| 1 Month Change | -6.63% |
| 3 Month Change | -28.10% |
| 1 Year Change | -71.44% |
| 3 Year Change | -83.37% |
| 5 Year Change | -84.97% |
| Change since IPO | -99.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| AJ8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | -1.0% |
| 1Y | -71.4% | -22.2% | 2.0% |
Return vs Industry: AJ8 underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: AJ8 underperformed the German Market which returned 2% over the past year.
Price Volatility
| AJ8 volatility | |
|---|---|
| AJ8 Average Weekly Movement | 16.2% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AJ8's share price has been volatile over the past 3 months.
Volatility Over Time: AJ8's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 389 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
| AJ8 fundamental statistics | |
|---|---|
| Market cap | €254.89m |
| Earnings (TTM) | -€228.49m |
| Revenue (TTM) | €145.20m |
1.8x
P/S Ratio-1.1x
P/E RatioIs AJ8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AJ8 income statement (TTM) | |
|---|---|
| Revenue | US$156.31m |
| Cost of Revenue | US$237.68m |
| Gross Profit | -US$81.37m |
| Other Expenses | US$164.61m |
| Earnings | -US$245.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -11.72 |
| Gross Margin | -52.05% |
| Net Profit Margin | -157.36% |
| Debt/Equity Ratio | -8.7% |
How did AJ8 perform over the long term?
See historical performance and comparison